Identification of treatment-resistant major depressive disorder using a machine learning algorithm

被引：0
|
作者：
Semeniuta, Daniel [1 ]
Marci, Carl [1 ]
Bandaria, Jigar [1 ]
Zabinski, Joseph W. [1 ]
Paulus, Jessica K. [1 ]
Orsini, Lucinda [2 ]
Boussios, Costas [1 ]
机构：
[1] OM1 Inc, Boston, MA USA
[2] Compass Pathways Ltd, London, England
来源：
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY | 2023年 / 32卷
关键词：
D O I：
暂无
中图分类号：
R1 [预防医学、卫生学];
学科分类号：
1004 ; 120402 ;
摘要：
956
引用
收藏
页码：447 / 447
页数：1
相关论文
共 50 条
  • [21] Treatment patterns in patients with treatment-resistant depression in Danish patients with major depressive disorder
    Gronemann, Frederikke Hordam
    Petersen, Janne
    Alulis, Sarah
    Jensen, Kristoffer Jarlov
    Riise, Jesper
    Ankarfeldt, Mikkel Zollner
    Solem, Espen Jimenez
    Bodker, Nikolaj
    Osler, Merete
    JOURNAL OF AFFECTIVE DISORDERS, 2021, 287 : 204 - 213
  • [22] Adjunctive quetiapine for treatment-resistant adolescent major depressive disorder: A case series
    Pathak, S
    Johns, ES
    Kowatch, RA
    JOURNAL OF CHILD AND ADOLESCENT PSYCHOPHARMACOLOGY, 2005, 15 (04) : 696 - 702
  • [23] Lamotrigine Induces Hair Loss in a Patient With Treatment-Resistant Major Depressive Disorder
    Solmi, Marco
    Tamiello, Gianni Ivo
    Manuli, Giuseppe
    AMERICAN JOURNAL OF THERAPEUTICS, 2017, 24 (05) : E611 - E612
  • [24] Olanzapine/fluoxetine combination, olanzapine, and fluoxetine in treatment-resistant major depressive disorder
    Thase, M. E.
    Corya, S. A.
    Osuntokun, O.
    Sanger, T. M.
    Case, M.
    Watson, S. B.
    Dube, S.
    INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY, 2006, 9 : S235 - S236
  • [25] Safety and efficacy of olanzapine plus fluoxetine in treatment-resistant major depressive disorder
    Shelton, R
    Tollefson, GD
    Tohen, M
    Jacobs, T
    Buras, W
    Spencer, K
    Gannon, KS
    Stahl, S
    SCHIZOPHRENIA RESEARCH, 1999, 36 (1-3) : 297 - 298
  • [26] Treatment-resistant major depressive disorder: Canadian expert consensus on definition and assessment
    Rybak, Yuri E.
    Lai, Ka S. P.
    Ramasubbu, Rajamannar
    Blumberger, Daniel M.
    Chan, Peter
    Delva, Nicholas
    Giacobbe, Peter
    Gosselin, Caroline
    Kennedy, Sidney H.
    Iskandar, Hani
    McInerney, Shane
    Ravitz, Paula
    Sharma, Verinder
    Zaretsky, Ari
    Burhan, Amer M.
    DEPRESSION AND ANXIETY, 2021, 38 (04) : 456 - 467
  • [27] Decreased fronto-limbic volumes in treatment-resistant major depressive disorder
    Serra-Blasco, M.
    Portella, M. J.
    De Diego-Adelino, J.
    Vives-Gilabert, Y.
    Gomez-Anson, B.
    Santos, A.
    Puigdemont, D.
    Alvarez, E.
    Perez, V.
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2012, 22 : S239 - S240
  • [28] Overcoming treatment-resistant major depressive disorder outside of the doctor's office
    Pereira, Jorge Mota
    Fonte, Daniela
    Teixeira, Ricardo Joao
    Carvalho, Serafim
    PSYCHIATRY RESEARCH, 2019, 279 : 397 - 398
  • [29] Olanzapine/fluoxetine combination, olanzapine, and fluoxetine in treatment-resistant major depressive disorder
    Thase, ME
    Corya, SA
    Osuntokun, O
    Sanger, TM
    Case, M
    Watson, SB
    Dubé, S
    BIOLOGICAL PSYCHIATRY, 2006, 59 (08) : 210S - 210S
  • [30] Towards new mechanisms: an update on therapeutics for treatment-resistant major depressive disorder
    Papakostas, G. I.
    Ionescu, D. F.
    MOLECULAR PSYCHIATRY, 2015, 20 (10) : 1142 - 1150
12345